Personalis (PSNL) EV/EBIT: History & Chart

Personalis, Inc.(PSNL)

Medical - Diagnostics & Research · Fremont, CA

$15.98-0.42 (-2.59%)

Delayed quote: Oct 6, 2026, 2:40 PM EDT

About Personalis, Inc.

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Fremont, CA

260 employees

www.personalis.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Christopher Hall

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Personalis, Inc. (PSNL)	$1.71B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.71B	8.87x	16.91x	16.91x	19.03x
Alignment Healthcare, Inc. (ALHC)vs ›	$1.72B	24.69x	614.86x	614.86x	614.86x
Zenas BioPharma, Inc. (ZBIO)vs ›	$1.69B	N/A	N/A	N/A	N/A
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.74B	N/A	N/A	N/A	N/A
Xeris Biopharma Holdings, Inc. (XERS)vs ›	$1.75B	52.38x	67.78x	67.78x	67.78x
Surgery Partners, Inc. (SGRY)vs ›	$1.77B	13.91x	14.36x	17.64x	18.88x
Alphatec Holdings, Inc. (ATEC)vs ›	$1.63B	N/A	33.08x	33.08x	33.08x
Ocular Therapeutix, Inc. (OCUL)vs ›	$1.63B	N/A	N/A	N/A	N/A
Novocure Ltd (NVCR)vs ›	$1.78B	N/A	783.33x	1393.80x	1393.80x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Personalis, Inc. (PSNL)

$1.71B

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.71B

8.87x

16.91x

19.03x